Bausch + Lomb Corporation (BLCO)
Why Bausch + Lomb Stock Soared by Over 7% on Monday
It was quite a busy and eventful day for the company.
Bausch & Lomb And Edgewise Therapeutics Are Among Top 7 Mid Cap Stock Gainers Last Week (Sept 15-Sept 21): Are The Others In Your Portfolio?
This week, the Federal Reserve's decision to reduce interest rates by 50 basis points boosted share prices across the technology, construction, industrial, machinery, and financial sectors.
Bausch + Lomb (BLCO) Surges 14.5%: Is This an Indication of Further Gains?
Bausch + Lomb (BLCO) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock doesn't suggest further strength down the road.
Why Bausch + Lomb Rallied Today
The Financial Times reported Bausch + Lomb is in talks with advisors to potentially sell itself. It had formerly sought to spin off from parent Bausch Health in a stock-for-stock deal.
Bausch + Lomb Stock Jumps Amid Reports Of A Sale
Bausch + Lomb (BLCO) shares popped Monday following a report that the eyecare company is considering a sale.
Bausch + Lomb Corporation (BLCO) Q2 2024 Earnings Call Transcript
Bausch + Lomb Corporation (NYSE:BLCO ) Q2 2024 Earnings Call July 31, 2024 8:00 AM ET Company Participants George Gadkowski - Vice President, Investor Relations Brent Saunders - Chairman and Chief Executive Officer Sam Eldessouky - Chief Financial Officer Conference Call Participants Xuyang Li - Jefferies Patrick Wood - Morgan Stanley Craig Bijou - Bank of America Robbie Marcus - JPMorgan Douglas Miehm - RBC Capital Markets Matt Miksic - Barclays Operator Good morning, and welcome to Bausch + Lomb's Second Quarter 2024 Earnings Call. [Operator Instructions] Please note, this event is being recorded.
Bausch + Lomb (BLCO) Reports Q2 Earnings: What Key Metrics Have to Say
While the top- and bottom-line numbers for Bausch + Lomb (BLCO) give a sense of how the business performed in the quarter ended June 2024, it could be worth looking at how some of its key metrics compare to Wall Street estimates and year-ago values.
Bausch + Lomb (BLCO) Matches Q2 Earnings Estimates
Bausch + Lomb (BLCO) came out with quarterly earnings of $0.13 per share, in line with the Zacks Consensus Estimate. This compares to earnings of $0.18 per share a year ago.
Analysts Estimate Bausch + Lomb (BLCO) to Report a Decline in Earnings: What to Look Out for
Bausch + Lomb (BLCO) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
